Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders
Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs
Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs
Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions
Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors
Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors
Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian
Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities
Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000
Cascadia To Participate in the Gentile Mining Investor Forum and Michael Gentile Mining & Metals European Roadshow
Spartan Metals Geophysical Surveys Indicate Potential Tungsten-Silver Veins Extension at Its Tungstonia Claims, Nevada
